Product Information
METHYLPHENIDATE 5 MG TABLET is a generic product labeled by SpecGx LLC, priced at $0.1268 per EA under NDC 00406114201. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 27, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
SpecGx LLCNDC
00406114201
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA040300FDA Approved
11/27/1998
TE Code
AB
On Market Since
11/27/1998
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE 5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 75.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1268 per EA |
|---|---|
| All-time high | $0.5825 (Feb 12, 2014) |
| All-time low | $0.0841 (Jul 17, 2024) |
| 52-week high | $0.1434 |
| 52-week low | $0.1268 |
| Median price | $0.1394 |
| Average price | $0.2411 |
| Largest weekly change | +55.5% (Aug 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 32% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SpecGx LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE 5 MG TABLET, manufactured by SpecGx LLC, is $0.1268 per EA (NDC 00406114201), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE 5 MG TABLET has declined 75.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE 5 MG TABLET?
Since Nov 28, 2013, the NADAC for METHYLPHENIDATE 5 MG TABLET has ranged from a low of $0.0841 (Jul 17, 2024) to a high of $0.5825 (Feb 12, 2014), with a median of $0.1394 per EA.
Are there cheaper alternatives to METHYLPHENIDATE 5 MG TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE 5 MG TABLET, is $0.0858 per EA — about 32% below METHYLPHENIDATE 5 MG TABLET.
Who manufactures METHYLPHENIDATE 5 MG TABLET?
METHYLPHENIDATE 5 MG TABLET (NDC 00406114201) is labeled by SpecGx LLC, and CMS classifies it as a generic product.